Premium
Side effects of systemic oncological therapies in dermatology
Author(s) -
Zimmer Lisa,
Vaubel Julia,
Livingstone Elisabeth,
Schadendorf Dirk
Publication year - 2012
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2012.07942.x
Subject(s) - medicine , vemurafenib , adverse effect , clinical trial , metastatic melanoma , melanoma , intensive care medicine , dermatology , skin cancer , cancer , oncology , cancer research
Summary The discovery of specific gene mutations, termed “driver mutations”, in different tumors has brought personalized medicine into the focus of cancer treatment. Targeted treatment agents generally are administered orally and have a tolerable adverse event profile; they have become widely used in both inpatient and outpatient settings. The approval of the selective BRAF inhibitor vemurafenib (Zelboraf®) as first‐line therapy of metastatic melanoma in Europe in February 2012 as well as the increasing use of MEK inhibitors within clinical trials confronts dermatologists and oncologists with a new spectrum of side effects. Knowledge of these possible adverse events and their management will be crucial for optimized patient care. This article offers an overview of the most important adverse events of currently employed dermato‐oncologic therapeutic agents.